Zadenvi 60mg solution for injection in pre-filled syringe patient reminder card
patient reminder card
Search by company, common medicine name, or title of Risk Minimisation Material
patient reminder card
This risk minimisation material is a condition of the marketing authorisation for ozanimod. The Prescriber's Checklist includes information on the ozanimod treatment initiation criteria (including re-initiation); monitoring parameters prior to, during and after treatment with ozanimod; counselling points for patients and pregnancy prevention for women of childbearing potential.
This risk minimisation material is a condition of the marketing authorisation for ozanimod. This card should be provided to women of childbearing potential receiving treatment with ozanimod. It contains information on the potential risks if ozanimod is used during pregnancy, how to minimise these risks through pregnancy prevention and what the patient should do if they become pregnant while on treatment with ozanimod.
This risk minimisation material is a condition of the marketing authorisation for ozanimod. This guide should be provided to patients, or caregivers of patients, receiving treatment with ozanimod as it provides important information including what patients need to be aware of before they start taking ozanimod, the signs and symptoms of important side effects they need to look out for during treatment and how to report side effects.
This reminder card contains important safety information that you need to be aware of before and during treatment with Zoledronic acid
Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.
This reminder card contains important safety information that you need to be aware of before and during treatment with Zoledronic acid 4 mg/5 ml concentrate for solution for infusion for cancer-related conditions.
A healthcare professional’s guide to minimizing risks with Zolgensma
Are you a healthcare professional?
Are you a healthcare professional?